A Phase 1 Study of Cosibelimab (CK-301; UNLOXCYT) in Combination With Lenalidomide in Patients With Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome

This phase I trial tests the safety, side effects and best dose of lenalidomide in combination with cosibelimab for the treatment of patients with mycosis fungoides or Sézary syndrome that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory).Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Immunotherapy with monoclonal antibodies, such as cosibelimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide in combination with cosibelimab may be safe and tolerable in treating patients with relapsed or refractory mycosis fungoides or Sézary syndrome.

Start Date16 May 2027

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT07605416

/ RecruitingPhase 2IIT

Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial

This phase II trial compares standard consolidation with daratumumab, carfilzomib, lenalidomide, and dexamethasone to consolidation with teclistamab following standard induction therapy and autologous hematopoietic stem cell transplant for improving overall survival of patients with plasma cell leukemia. Consolidation therapy is treatment given after initial therapy to kill any cancer cells that may remain in the body. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Carfilzomib inhibits protein complexes called proteasomes, which inhibits cancer cell growth and leads to cancer cell death. Lenalidomide may help kill cancer cells and prevents the growth of blood vessels that cancer cells need to survive. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Teclistamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Giving teclistamab as consolidation therapy after induction and autologous hematopoietic stem cell transplant may improve survival outcomes in patients with plasma cell leukemia, compared to standard consolidation with daratumumab, carfilzomib, lenalidomide, and dexamethasone.

Start Date20 Apr 2027

Sponsor / Collaborator

National Cancer Institute

NCT07029776

/ Not yet recruitingPhase 2

A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)

The purpose of this research is to learn whether using teclistamab and talquetamab at different time points will improve survival in participants with high-risk Multiple Myeloma (MM).
The treatment on this study will consist of Induction chemotherapy and stem cell collection, Immunotherapy 1 chemotherapy and Immunotherapy 2 chemotherapy. For participants whose testing show they are Minimal Residual Disease (MRD) positive (still have myeloma cells present in the bone marrow testing), a Melphalan-based stem cell transplant will be performed. For participants whose testing show they are MRD negative, the stem cell transplant will not be performed. All participants will go on to receive Immunotherapy 3 chemotherapy, Immunotherapy 4 chemotherapy, and Maintenance therapy.

Start Date01 Mar 2027

Sponsor / Collaborator

University of Arkansas Fort Smith

[+1]

100 Clinical Results associated with Lenalidomide

100 Translational Medicine associated with Lenalidomide

100 Patents (Medical) associated with Lenalidomide

8,691

Literatures (Medical) associated with Lenalidomide

01 Mar 2027·Value in Health Regional Issues

Cost-Minimization Analysis of Intravenous and Subcutaneous Daratumumab in Patients With Multiple Myeloma: A Societal and Healthcare System Perspective

Article

Author: Fantelli, Valentina ; Temporin, Francesca ; Venturini, Francesca ; Riccoboni, Debora ; Zambello, Renato ; Berti, Giacomo

OBJECTIVES:

We compared costs of daratumumab (DARA) subcutaneous (SC) versus intravenous (IV) from societal and healthcare system perspectives.

METHODS:

We performed a cost-minimization analysis over 24 months using real-world weight distribution data from 304 patients treated in 2024. IV drug costs were weighted by patient distribution across 14 weight categories (6.25 kg intervals). We analyzed 4 patient scenarios (employed/unemployed, with/without caregiver) and 2 regimens (DARA-lenalidomide-dexamethasone, DARA-bortezomib-dexamethasone). Costs included drug acquisition, preparation materials, personnel time, and productivity losses. Probabilistic sensitivity analysis (10 000 Monte Carlo simulations) assessed robustness to weight distribution uncertainty. Break-even analysis identified weight thresholds at which formulations were cost equivalent.

RESULTS:

Initial IV administration required 1104 minutes versus 22 minutes for SC; subsequent IV administrations required 392 minutes. Weighted average IV drug cost was €5579 versus €5652 for SC. From a societal perspective, SC generated savings of €1125 to €11 899 across all scenarios. Probabilistic analysis showed 100% probability of SC cost saving (mean €5839; 95% CI €2204-€14 317), with weight distribution uncertainty contributing only 2% of total cost variability. Break-even analysis showed IV was marginally cheaper only in patients < 68.75 kg (42.9% of cohort). From the healthcare provider perspective, SC generated higher net revenues (€308 versus €175 per administration); payer costs remained neutral (€315 per administration regardless of route).

CONCLUSIONS:

SC DARA provides robust economic advantages across all regimens, patient scenarios, and time horizons. Despite marginal cost advantages for IV in less weight patients, the comprehensive clinical and operational benefits strongly support SC as the preferred administration route.

01 Jan 2027·CELLULAR SIGNALLING

Lenalidomide triggers ferroptosis in multiple myeloma by blocking the c-Maf/USP7 signaling pathway to induce the ubiquitination and degradation of FTH1

Article

Author: Cui, Jianan ; Zhang, Erhao ; Xu, Jintao ; Lin, Zenghua ; Jia, Hui ; Zhang, Tenglong ; Xu, Liqin ; Huang, Hongming ; Xu, Jinjin ; Zhang, Yufei ; Li, Xiaomin ; Zhang, Tingting ; Guo, Dan

Multiple myeloma (MM) is the second most common hematological malignancy. Ferroptosis, a distinct form of programmed cell death, has attracted the interest of researchers because of its unique role and biological significance across various diseases. As a first-line clinical treatment drug for MM, lenalidomide (LEN) has shown remarkable therapeutic efficacy. Accumulating evidence has highlighted the significant role of LEN in MM treatment; however, to date, no studies have investigated its potential efficacy in the ferroptosis pathway of MM and the underlying mechanisms. To investigate the therapeutic effects of LEN on MM, several in vitro and in vivo experiments were performed. Our data confirmed that LEN exerts antitumor activity in a dose-dependent manner by inducing ferroptosis, which is characterized by an abnormal increase in ROS and MDA levels, a decrease in GSH levels and mitochondrial membrane potential, and iron overload. Mechanistically, in vitro experiments have revealed that LEN directly targets the c-Maf protein and subsequently suppresses USP7 transcription, thereby inducing FTH1 degradation via the ubiquitin-proteasome pathway, triggering ferroptosis in MM cells. Finally, in vivo experiments demonstrated that LEN (10 mg/kg) significantly suppresses the c-Maf/USP7/FTH1 signaling pathway, further inhibiting MM growth by triggering ferroptosis. In conclusion, this study is the first to demonstrate that LEN suppresses MM by inducing ferroptosis via FTH1-dependent iron homeostasis, suggesting that the ferroptosis induced by the c-Maf/USP7/FTH1 signaling pathway during LEN treatment is a novel mechanism underlying its antitumor activity.

31 Dec 2026·RENAL FAILURE

Noncrystalline light-chain proximal tubulopathy: a retrospective study from a single institute of China

Article

Author: Zhao, Ming-hui ; Wang, Yu-hua ; Wang, Su-xia ; Yao, Jie-qiong ; Yu, Xiao-juan ; Yang, Li ; Zhang, Xu ; Zhou, Fu-de

Light-chain proximal tubulopathy (LCPT) is a rare disease, which is classified as crystalline or noncrystalline based on the cytoplasmic inclusions in the proximal tubules. This study aimed to investigate the clinical features of noncrystalline LCPT from a single institute of China. We retrospectively enrolled patients diagnosed with isolated noncrystalline LCPT by kidney biopsy at Peking University First Hospital between 2011 and 2024. We systematically analyzed clinical data, kidney pathological type, treatment and prognosis. Twenty patients were enrolled. The mean age at diagnosis was 58 ± 12 and the sex ratio was 4/16 (female/male). Mean proteinuria was 1.9 ± 2.3g/24 hr and the mean estimated glomerular filtration rate (eGFR) at the point of biopsy 57 ± 30 mL/min/1.73 m². κ-light chain restriction (70%) was dominant among patients with noncrystalline LCPT. An abnormal serum free light chain ratio was detected in 50% of the patients. Proximal tubulopathy without cytoplasmic inclusions/acute tubular injury (60%) was the most common type, followed by proximal tubulopathy with lysosomal indigestion/constipation (25%) and tubulopathy associated with interstitial inflammation reaction (15%). During follow-up, patients received bortezomib-based or R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) or a daratumumab-lenalidomide-dexamethasone combination (DRD) chemotherapy vs. supportive treatment only. The mean follow-up time was 24 ± 22 months. All patients showed improved or stable kidney function during the observation period. This represents the first case series detailing noncrystalline LCPT with distinct pathological subtypes in northern China. Chemotherapy targeting aberrant plasma cell clones might favor kidney outcomes in patients with noncrystalline LCPT.

1,259

News (Medical) associated with Lenalidomide

06 Nov 2026

·www.biospace.com

Genmab Announces Financial Results for the Nine Months of 2026

November 5, 2026 Copenhagen, Denmark; Interim Report for the Nine Months Ended September 30, 2026 Highlights Epcoritamab approved in Europe (as TEPKINLY ® ) and Japan (as EPKINLY ® ) in combination with R² for the treatment of adult patients with relapsed or refractory FL Initiation of two new Phase 3 trials for petosemtamab in first- and second-line CRC Genmab revenue increase d 22% compared to the first nine months of 2025 , to $3,238 million “The third quarter of 2026 reinforced the breadth of our late-stage portfolio. TEPKINLY plus R 2 became the first bispecific-based therapy approved in Europe for second-line FL, extending epcoritamab's reach as a core therapy across B-cell malignancies. We also broadened our petosemtamab program with new Phase 3 studies in CRC, underscoring our confidence in this asset beyond head and neck cancer. As anticipated, we are now in our data-rich fourth quarter, where we have delivered pivotal readouts across our three late-stage assets, epcoritamab, Rina-S ® (rinatabart sesutecan) and petosemtamab, supporting multiple regulatory submissions and potential launches in 2027,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. Financial Performance First Nine Months of 2026 Revenue was $3,238 million for the first nine months of 2026 compared to $2,662 million for the first nine months of 2025. The increase of $576 million, or 22%, was primarily driven by higher DARZALEX ® and Kesimpta ® royalties and higher EPKINLY ® net product sales. Royalty revenue was $2,699 million in the first nine months of 2026 compared to $2,219 million in the first nine months of 2025, an increase of $480 million, or 22%. The increase in royalties was driven by higher net sales of DARZALEX and Kesimpta. Net sales of DARZALEX by J&J were $12,410 million in the first nine months of 2026 compared to $10,448 million in the first nine months of 2025, an increase of $1,962 million or 19%. Global net sales of EPKINLY/TEPKINLY ® were $491 million in the first nine months of 2026 compared to $333 million in the first nine months of 2025, an increase of $158 million or 47%. Cost of product sales were $234 million for the first nine months of 2026 compared to $157 million for the first nine months of 2025. The increase of $77 million, or 49%, was primarily driven by the profit-sharing amounts payable to AbbVie related to EPKINLY sales. Acquisition and integration related charges related to the integration of Merus were $87 million in the first nine months of 2026. Amortization of acquired intangible assets was $35 million for the first nine months of 2026 compared to $9 million for the first nine months of 2025. The increase of $26 million, was primarily driven by the amortization of the Merus technology platform. Operating expenses were $2,018 million in the first nine months of 2026 compared to $1,498 million in the first nine months of 2025, an increase of $520 million or 35%. Adjusted operating expenses, which exclude Acquisition and integration related charges and Amortization of acquired intangible assets, were $1,896 million for the first nine months of 2026 compared to $1,489 million for the first nine months of 2025. The increase of $407 million, or 27%, was primarily driven by investment in our product pipeline, including the advancement of Rina-S and petosemtamab, and our global commercialization capabilities in preparation for their anticipated launches. Operating profit was $986 million in the first nine months of 2026 compared to $1,007 million in the first nine months of 2025. Adjusted operating profit, which excludes Acquisition and integration related charges and Amortization of acquired intangible assets, was $1,108 million in the first nine months of 2026 compared to $1,016 million in the first nine months of 2025. Non-IFRS Financial Measures Our Adjusted operating expenses and adjusted operating profit excludes acquisition and integration related charges and amortization of acquired intangible assets. These charges were recognized in current as well as prior periods and will likely reoccur in future periods. These items are excluded from operating expenses and operating profit because the Company believes they neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance. Non-IFRS information is intended to portray the results of our baseline performance, supplement or enhance management's, analysts' and investors’ overall understanding of our underlying financial performance and facilitate comparisons among current, past and future periods. This information is not intended to be considered in isolation or as a substitute for the related financial measures prepared in accordance with IFRS and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. The reconciliations of financial performance from IFRS to Non-IFRS for the first nine months of 2026 and 2025 were as follows: 2026 Actual Exclude 2026 Adjusted 2025 Actual Exclude 2025 Adjusted (USD million) IFRS A&I* Amort** Non-IFRS IFRS A&I* Amort** Non-IFRS Operating Expenses / Adj. Operating Expenses*** $ (2,018) 87 35 $ (1,896) $ (1,498) — 9 $ (1,489) Operating Profit / Adj. Operating Profit $ 986 87 35 $ 1,108 $ 1,007 — 9 $ 1,016 * Acquisition and integration related charges ** Amortization of intangible assets acquired through acquisitions ***Includes all expenses presented within Total costs and operating expenses, less cost of product sales. Key Company Events Post-Quarter End October: Positive topline results from the Phase 3 EPCORE ® DLBCL-2 trial evaluating fixed treatment duration epcoritamab in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of 2 to 5. Data will be submitted for presentation at a future medical meeting. Genmab and AbbVie Inc. (AbbVie) will engage global regulatory authorities to determine next steps. October: Positive topline results from the global Phase 3 RAINFOL™-02 trial of Rina-S in patients with platinum-resistant ovarian cancer (PROC) regardless of Folate Receptor Alpha (FRα) expression level or prior treatment with mirvetuximab. The trial met its primary endpoint of progression-free survival (PFS), with Rina-S demonstrating a statistically significant and clinically meaningful improvement compared with investigator’s choice chemotherapy in the intent-to-treat (ITT) and in the primary analysis set (PAS) populations. Based on these results, Genmab plans to engage with regulatory authorities worldwide regarding potential next steps. The data will also be submitted for presentation at a future medical meeting. October: Positive topline results from the global Phase 3 LiGeR-HN1 trial (NCT06525220) evaluating petosemtamab in combination with pembrolizumab versus pembrolizumab in patients with first-line (1L) PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The trial met both of its primary endpoints of overall survival (OS) and objective response rate (ORR), regardless of HPV status. Based on these positive topline results, Genmab plans to engage global regulatory authorities and will submit the full results from LiGeR-HN1 for presentation at a future medical meeting. Outlook Genmab is maintaining its 2026 financial guidance published August 6, 2026. Conference Call Genmab will hold a conference call to discuss the results for the first nine months of 2026 today, Thursday, November 5, at 6:00 pm CET, 5:00 pm GMT or 12:00 pm EST. To join the call please use the below registration link. Registered participants will receive an email with a link to access dial-in information as well as a unique personal PIN: . A live and archived webcast of the call and relevant slides will be available at . Contact Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs T: +1 609 524 0065; E: mmp@genmab.com Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: acn@genmab.com R 2 = rituximab and lenalidomide; FL = follicular lymphoma; CRC = colorectal cancer The Interim Report contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at . Genmab does not undertake any obligation to update or revise forward looking statements in the Interim Report nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo ® ; HuMax ® ; DuoBody ® ; HexaBody ® ; DuoHexaBody ® ; HexElect ® ; KYSO ® , ABBIL1TY™, RAINFOL™; ProfoundBio™ and Rina-S ® are trademarks of ProfoundBio, U.S., Co. and Genmab (Suzhou) Co., Ltd. Tivdak ® is a trademark of Seagen Inc.; EPCORE ® , EPKINLY ® , TEPKINLY ® and their designs are trademarks of AbbVie Biotechnology Ltd.; Biclonics ® and BIZENGRI ® are registered trademarks of Merus N.V. Kesimpta ® and Sensoready ® are trademarks of Novartis AG or its affiliates; DARZALEX ® , DARZALEX FASPRO ® , RYBREVANT ® , RYBREVANT FASPRO™, TECVAYLI ® and TALVEY ® are trademarks of Johnson & Johnson; TEPEZZA ® is a trademark of Horizon Therapeutics Ireland DAC. Download the full Interim Report for the First Nine Months of 2026 on attachment or at . CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 Genmab A/S Carl Jacobsens Vej 30 2500 Valby Denmark Attachment 20261105_CA45_Genmab Interim Report Q3 2026

Clinical ResultPhase 3Financial StatementDrug ApprovalBiosimilar

06 Nov 2026

·www.biospace.com

BostonGene Showcases Biologically Grounded AI at ACR Convergence 2026 to Advance Precision Rheumatology and Autoimmune Disease Stratification

Biologically grounded AI models decode tissue complexity to uncover shared disease drivers across autoimmune indications WALTHAM, Mass.--(BUSINESS WIRE)-- BostonGene , developer of an AI model for tumor and immune biology, announced today that it will present new data demonstrating the application of its biologically grounded AI in non-oncology indications at the American College of Rheumatology (ACR) Convergence 2026. ACR Convergence 2026, the world's premier rheumatology event, will be held November 6–11 at the Orange County Convention Center in Orlando, Florida. BostonGene combines multimodal profiling with biologically grounded AI to decode complex immune system signals and disease architectures. By mapping the cellular architecture of healthy and inflamed tissues, the company’s advanced analytical platform uncovers mechanistic drivers of inflammation and autoimmunity, differentiates shared immune pathways from tissue-specific signatures, and enables precise patient stratification to optimize therapeutic development. BostonGene session details: Abstract: 1086 Title: A Pan-Autoimmune Tissue Transcriptomic Atlas Reveals Distinct Baseline Architectures and Disease-Associated Immune Shifts Across Immune-Mediated Inflammatory Diseases Date & time: November 9 | 10:30 AM – 12:30 PM Presenter: Michael Goldberg, PhD, BostonGene Drug development in immune-mediated inflammatory diseases (IMIDS) is limited by substantial biological heterogeneity within diagnoses and overlapping mechanisms across diseases. To address this gap, we developed a pan-autoimmune transcriptomic atlas that maps baseline healthy and diseased tissue architectures across immune-mediated inflammatory diseases (IMIDs) spanning skin, synovium, colon, and ileum. This reference framework distinguishes shared immune features (M1 macrophage shift, Treg enrichment) from tissue- and disease-specific drivers (including Th1/Th17, B-cell/TLS, and myeloid/IFN). This approach enables the development of mechanistically grounded stratification hypotheses across diverse IMIDs and supports matching patient subgroups with therapeutic classes aligned with their underlying biological drivers. To learn more or to schedule a meeting with BostonGene during the event, please contact Lili DeTraglia at events@bostongene.com . For more information, please visit the ACR Convergence 2026 website . About BostonGene Corporation BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. For more information, visit . Contacts Media Contact: BostonGene Erin Keleher +1-617-283-2285 Erin.Keleher@BostonGene.com

05 Nov 2026

·www.biopharmadive.com

At ASH, drugmakers to showcase early data for three-pronged cancer therapies

More than a decade ago, Amgen ushered in a new era of cancer care, bringing to market the first bispecific antibody designed to treat a malignancy.The 2014 clearance of that drug, Blincyto, in leukemia kickstarted whats since become a massive research push to widen the use of these treatments in oncology. Since then, Johnson & Johnson, AbbVie and Pfizer, among others, have successfully developed bispecific treatments for other blood cancers like multiple myeloma and lymphoma. Another, from Amgen, came to market for a type of lung cancer.The upcoming American Society of Hematology meeting will showcase early data on what could prove to be another step forward. Abstracted data published on Wednesday showed that the meeting will feature multiple presentations on trispecific antibodies that bind to three targets instead of two. Drugmakers hope these three-pronged medicines could be better equipped to counter the tricks tumors use to resist treatment and, as a result, have longer-lasting effects.J&J and AbbVie are among the leaders in developing trispecifics for multiple myeloma. Both have medicines in Phase 2 and Phase 1 testing, respectively, thatll be showcased at ASH. But theyre flanked by China-based drugmakers Innovent Biologics and Shanghai Xianxiang Medical Technology, which are also presenting early data at the meeting. Kali Therapeutics, a Californian biotech startup, will spotlight preclinical research as well.J&Js prospect, ramantamig, binds to an immune cell target called CD3 and, on diseased multiple myeloma cells, the proteins BCMA and GPRC5D. J&J has approved bispecifics that individually target either BCMA or GPRC5D. Both of those medicines,Tecvayli and Talvey, have shown in testingthey can cut the risk of disease progression or death in people with relapsed or resistant disease.At ASH, J&J will present from a mid-stage trial testing ramantamig alongside Darzalex and Revlimid as an induction treatment in newly diagnosed multiple myeloma patients who are eligible for bone marrow transplants. A data abstract posted Wednesday indicated that all 20 patients who were evaluable after three cycles of treatment had minimal residual disease negativity, or no detectable diseased cells.The abstract provides strong early data that suggests J&J could add another important asset to its already broad treatment portfolio in multiple myeloma, wrote RBC Capital Markets analysts in a Thursday client note.AbbVie, meanwhile, will reveal data for a trispecific called ABBV-2001 that was licensed from Ichnos Glenmark. AbbVies drug binds to CD3, BCMA and another receptor called CD38. In Phase 1 testing in people with relapsed or refractory disease, the drug stimulated responses in 75% to 85% of enrollees. Additionally, 83% to 88% of those who achieved a complete response, or had no active signs of cancer, also achieved MRD-negative status.Innovents trispecific, IBI3003, targets the same receptors as ramantamig. The drug was associated with similarly high response rates in a Phase 1 trial in people with late-stage disease, too. That number was 77% among patients receiving the dose selected for Phase 2.A competing trispecific from Shanghai Xianxiang, called SIM0500, achieved an overall response rate as high as 86% at the highest doses tested. '

Phase 1Clinical ResultDrug ApprovalPhase 2ASH

100 Deals associated with Lenalidomide

External Link

KEGG	Wiki	ATC	Drug Bank
D04687	Lenalidomide	L04AX04	DB00480

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Large B-cell lymphoma	United States	Seagen, Inc.	11 Feb 2025
Marginal Zone B-Cell Lymphoma	United States	Bristol Myers Squibb Co.	28 May 2019
Adult T-Cell Leukemia-Lymphoma	Japan	Bristol-Myers Squibb KK	02 Mar 2017
Chromosome 5q Deletion Syndrome	European Union	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Chromosome 5q Deletion Syndrome	Iceland	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Chromosome 5q Deletion Syndrome	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Chromosome 5q Deletion Syndrome	Norway	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	European Union	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	Iceland	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	Norway	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	European Union	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	Iceland	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	Norway	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	European Union	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	Iceland	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	Norway	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Multiple Myeloma	United States	Bristol Myers Squibb Co.	29 Jun 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Crouzon Syndrome With Acanthosis Nigricans	Phase 3	Japan	Chugai Pharmaceutical Co., Ltd.	07 Mar 2024
Cytopenia	Phase 3	Japan	Chugai Pharmaceutical Co., Ltd.	07 Mar 2024
Hyperhidrosis	Phase 3	Japan	Chugai Pharmaceutical Co., Ltd.	07 Mar 2024
Pain	Phase 3	Japan	Chugai Pharmaceutical Co., Ltd.	07 Mar 2024
Thromboembolism	Phase 3	Japan	Chugai Pharmaceutical Co., Ltd.	07 Mar 2024
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	United States	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Japan	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Argentina	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Australia	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Austria	Incyte Corp.	11 May 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2026	Not Applicable	Multiple Myeloma Maintenance	43	Daratumumab+Lenalidomide maintenance	bxbgqzbbjz(ffgutlfraj) = bfrtutoonp sippubxpsl (eupnlbgtht ) View more	Positive	12 Dec 2026
NCT04436107 (BGB-3111-110, ASH2026)	Phase 1	Diffuse Large B-Cell Lymphoma CD79B ITAM mutations \| B2M mutations	50	Zanubrutinib + Lenalidomide (CD79B ITAM mutations)	bxavzzauws(tjrlyblsfr) = yjicfvpjvu hmybmqodqe (yavwhvygrx ) View more	Positive	12 Dec 2026
NCT04436107 (BGB-3111-110, ASH2026)	Phase 1		50	Zanubrutinib + Lenalidomide (others)	bxavzzauws(tjrlyblsfr) = jhivfgegrc hmybmqodqe (yavwhvygrx ) View more	Positive	12 Dec 2026
NCT06549335 (ASH2026)	Phase 2	Follicular Lymphoma First line	60	Lenalidomide, Zanubrutinib plus Obinutuzumab (ZGR)	eogoumzrwa(klfbcvvfzv) = micmerxciq euitxgrqyx (lqkdzgyjsx ) View more	Positive	12 Dec 2026
NCT03729804 (COBRA, ASH2026)	Phase 3	Multiple Myeloma	250	Carfilzomib-lenalidomide-dexamethasone (KRd)	ivkqgomfyx(nyjlqxkbor) = hmjturhswd zyhdczkogr (xtgreqneqk ) View more	Positive	12 Dec 2026
NCT03729804 (COBRA, ASH2026)	Phase 3	Multiple Myeloma	250	Bortezomib-lenalidomide-dexamethasone (VRd)	ivkqgomfyx(nyjlqxkbor) = yenuxeavkp zyhdczkogr (xtgreqneqk ) View more	Positive	12 Dec 2026
ASH2026	Not Applicable	Diffuse Large B-Cell Lymphoma First line	21	Polatuzumab vedotin+rituximab+acalabrutinib+lenalidomide	ommooxduvs(kgrkitjxyh) = Grade 3-4 neutropenia and thrombocytopenia occurred in 32% and 10.5%, respectively. Two patients developed rash, which resolved with corticosteroids and intravenous immunoglobulin. No atrial fibrillation, major bleeding, or clinically significant organ toxicity was observed. czwmaslqtb (ytgzudcpdk ) View more	Positive	12 Dec 2026
ASH2026	Not Applicable	Multiple Myeloma First line	520	Daratumumab, lenalidomide, and dexamethasone	bkmflhzqgd(lclspayhly) = Lenalidomide and dexamethasone dose modifications occurred in 85% of evaluable pts, while daratumumab or lenalidomide discontinuation due to toxicity or intolerance occurred in 21%. Grade ≥3 infections occurred in 19%, VTE in 7%, and lenalidomide-associated rash in 8%. ujksbcmnpc (wxdwufzege )	Positive	12 Dec 2026
ASH2026	Not Applicable	Multiple Myeloma First line	992	Daratumumab+Lenalidomide+Dexamethasone	gyatxzmiez(wewghwghon) = afhhdxnxgr jbpyigwrzs (bzhcqxeldh, 84.1 - 89.2) View more	Positive	12 Dec 2026
NCT04939844 (MajesTEC-5, ASH2026)	Phase 2	Multiple Myeloma First line \| Induction	21	Ramantamig+Daratumumab+Lenalidomide	erigzrbpje(roqnobpuid) = pvilgiqomu ywfixpaaik (pmlnqtmipt ) View more	Positive	12 Dec 2026
NCT03863184 (ASH2026)	Phase 2	Mantle-Cell Lymphoma First line	34	Acalabrutinib + Lenalidomide + Rituximab	qdctkyvdfd(prkqgocuwh) = sgblniwahc xccsxyuzxt (fgcgxbcfna, 81 - 100) View more	Positive	12 Dec 2026
NCT03863184 (ASH2026)	Phase 2	Mantle-Cell Lymphoma First line	34	Acalabrutinib + Lenalidomide + Obinutuzumab	qdctkyvdfd(prkqgocuwh) = xhcaoyrajt xccsxyuzxt (fgcgxbcfna, 100 - 100) View more	Positive	12 Dec 2026
ASH2026	Not Applicable	Multiple Myeloma	194	Lenalidomide maintenance	rrkpalbdbc(mjxbcviifw) = jxekonpytv uvqxcvjhzf (pnrggplxwo ) View more	Positive	12 Dec 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis